文献速递血栓与止血

Rozanolixizumab(FcRn抑制剂)治疗原发性免疫性血小板减少症患者的多剂量2期研究

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.
PubMed 文献 · Blood Adv · 2020-01-01

这项2期多中心开放标签研究纳入66例持续性/慢性原发性免疫性血小板减少症患者,接受每周1次皮下注射rozanolixizumab(累积剂量15-21 mg/kg)1至5次。所有不良事件均为轻至中度,最常见为头痛(39.4%),无治疗相关严重不良事件。单次15和20 mg/kg组分别有66.7%和54.5%患者至少一次达到血小板≥50×10^9/L,至第8天超过50%患者达到临床相关血小板应答,与IgG最低均值同时出现。

要点

  • 66例中51例(77.3%)报告不良事件,均为轻至中度,最常见头痛26例(39.4%),其中15例为治疗相关。
  • 4例发生严重不良事件但均非治疗相关,无因不良事件停药,无严重感染发生。
  • 单次15和20 mg/kg组分别66.7%和54.5%患者达到血小板≥50×10^9/L,至第8天超过50%患者达临床相关血小板应答。

核心结论

  • 在持续性/慢性原发性免疫性血小板减少症患者中,rozanolixizumab显示出良好的安全性特征和快速、显著的血小板升高,并与显著的IgG降低一致,尤其是单次给药时。
  • 这些数据支持rozanolixizumab在持续性/慢性原发性免疫性血小板减少症中开展3期研发。

研究设计与样本

  • 2期、多中心、开放标签研究,纳入持续性/慢性原发性免疫性血小板减少症患者66例。
  • 患者接受每周1次皮下输注rozanolixizumab 1至5次,累积剂量15-21 mg/kg。
  • 主要目标为安全性和耐受性,次要目标为临床疗效(血小板计数变化)和药效学效应(IgG变化)。

主要发现

  • 66例中51例(77.3%)报告1项或以上不良事件,均为轻至中度,最常见为头痛26例(39.4%),其中15例为治疗相关。
  • 4例患者发生严重不良事件,但均非治疗相关;无不良事件导致研究药物停用;无严重感染发生。
  • 多次输注后(5×4、3×7或2×10 mg/kg)至少一次达到血小板≥50×10^9/L的患者分别为35.7%、35.7%和45.5%;单次输注(15或20 mg/kg)分别为66.7%和54.5%。
  • 较高剂量(15和20 mg/kg)单次给药队列中,IgG最低均值和血小板最高均值均出现在第8天;多次给药队列中血小板最高值出现在第11天及以后。
  • IgA、IgM、IgE或白蛋白水平无临床有意义的变化。

关键数值与推荐

  • 单次15和20 mg/kg队列中,至第8天超过50%患者达到临床相关血小板应答(≥50×10^9/L),与IgG最低均值同时出现。
  • 多次输注5×4、3×7、2×10 mg/kg后至少一次达到血小板≥50×10^9/L的患者比例分别为35.7%、35.7%、45.5%。
  • 单次输注15和20 mg/kg后至少一次达到血小板≥50×10^9/L的患者比例分别为66.7%和54.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary immune thrombocytopenia (ITP) is a predominantly immunoglobulin G (IgG)-autoantibody-mediated disease characterized by isolated thrombocytopenia. Rozanolixizumab, a subcutaneously infused humanized monoclonal anti-neonatal Fc receptor (FcRn) antibody, reduced serum IgG in healthy volunteers. In this phase 2, multicenter, open-label study, patients with persistent/chronic primary ITP received 1 to 5 once-weekly subcutaneous infusions of rozanolixizumab (cumulative doses, 15-21 mg/kg). Primary objectives were safety and tolerability, and secondary objectives were clinical efficacy (change in platelet count) and pharmacodynamic effect (change in IgG). In all, 51 (77.3%) of 66 patients reported 1 or more adverse events (AEs), all mild-to-moderate, most commonly headaches (26 [39.4%] of 66), of which 15 were treatment related. Four patients had serious AEs, but none were treatment related. No AEs resulted in discontinuation of the study drug. No serious infections occurred. Platelet counts of ≥50 × 109/L were achieved at least once at any time after multiple infusions (5 × 4, 3 × 7, or 2 × 10 mg/kg: 35.7%, 35.7%, and 45.5% of patients, respectively) or single infusions (15 or 20 mg/kg: 66.7% and 54.5% patients, respectively). Minimum mean IgG levels and maximum mean platelet counts both occurred by day 8 in the higher (15 and 20 mg/kg) single-dose cohorts and maximum platelet count occurred by day 11 onward in the multiple-dose cohorts. No clinically meaningful changes occurred in IgA, IgM, IgE, or albumin levels. In patients with persistent/chronic primary ITP, rozanolixizumab demonstrated a favorable safety profile and rapid, substantial platelet increases concordant with substantial IgG reductions, especially with single doses. By day 8, in the 15 and 20 mg/kg single-dose cohorts, >50% patients achieved clinically relevant platelet responses (≥50 × 109/L), coinciding with the lowest mean IgG levels. These data support phase 3 development of rozanolixizumab in persistent/chronic primary ITP. This trial was registered at www.clinicaltrials.gov as #NCT02718716.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Robak T, Kaźmierczak M, Jarque I, et al. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Adv. 2020. PMID: 32886753. doi:10.1182/bloodadvances.2020002003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。